Efficacy and safety of ixekizumab in patients with active psoriatic arthritis with and without concomitant conventional disease-modifying antirheumatic drugs: SPIRIT-P1 and SPIRIT-P2 3-year results
COATES L., Mease P., Kronbergs A., Helt C., Sandoval D., Park SY., Combe B., Nash P., Deodhar A.